Literature DB >> 2475498

Insulin suppresses hepatitis B surface antigen expression in human hepatoma cells.

C K Chou1, T S Su, C M Chang, C P Hu, M Y Huang, C S Suen, N W Chou, L P Ting.   

Abstract

The human hepatoma Hep3B cells contain integrated hepatitis B viral genome and continually secret hepatitis B surface antigen (HBsAg). The production of HBsAg (but not alpha-fetoprotein) was suppressed by addition of low concentrations (0.1-1 nM) of insulin into serum-free medium. In addition, the suppression of HBsAg production by insulin was paralleled with the decrease in HBsAg mRNA abundance. Insulin also cause a rapid rate of disappearance of HBsAg mRNA (t 1/2, 2 h) in Hep3B cells. The Hep3B cells carry specific receptor with high affinity for insulin (Kd = 1.8 nM). The receptor showed an insulin-dependent protein tyrosine kinase activity. The half-maximal insulin concentration for the activation of the receptor kinase was about 5 nM. Only very high concentrations of insulin-like growth factor I and human proinsulin can compete for the insulin receptor binding and suppress HBsAg production, this suggests that insulin may act through its receptor binding to suppress HBsAg expression in human hepatoma Hep3B cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475498

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

Review 1.  Regulation of gene expression by insulin.

Authors:  R M O'Brien; D K Granner
Journal:  Biochem J       Date:  1991-09-15       Impact factor: 3.857

2.  Regulation of hepatitis B virus replication by the ras-mitogen-activated protein kinase signaling pathway.

Authors:  Yanyan Zheng; Jie Li; Deborah L Johnson; Jing-hsiung Ou
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles.

Authors:  Natalia Freitas; Celso Cunha; Stephan Menne; Severin O Gudima
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.